Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy

Published:2021-06-08 Issue:9 Volume:28 Page:1256-1264
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Smith David A.¹²,Bradshaw Daniel³^ORCID,Mbisa Jean L³,Manso Carmen F.³,Bibby David F³,Singer Joshua B⁴,Thomson Emma C⁴^ORCID,da Silva Filipe Ana⁴,Aranday‐Cortes Elihu⁴,Ansari M. Azim¹,Brown Anthony¹,Hudson Emma¹,Benselin Jennifer⁵,Healy Brendan⁶,Troke Phil⁷,McLauchlan John⁴,Barnes Eleanor¹²,Irving William L.⁵^ORCID

Affiliation:

1. Nuffield Department of Medicine Peter Medawar Building for Pathogen Research University of Oxford Oxford UK

2. NIHR Oxford Biomedical Research Centre Oxford UK

3. National Infection Service Public Health England London UK

4. MRC‐University of Glasgow Centre for Virus Research Glasgow UK

5. NIHR Biomedical Research Centre (BRC) Nottingham University Hospitals NHS Trust and the University of Nottingham Nottingham UK

6. Public Health Wales Microbiology Cardiff University Hospital of Wales Cardiff UK

7. Gilead Sciences Ltd London UK

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13549

Reference28 articles.

1. Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial

2. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection

3. Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

4. Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries

5. Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapy;Exploration of Digestive Diseases;2024-06-18

2. Real‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir;Alimentary Pharmacology & Therapeutics;2024-05-02

3. Effects of comorbid conditions and prescribed chronic medications on the treatment plan for chronic hepatitis C infection: A cross‐sectional retrospective study;Health Science Reports;2024-04-29

4. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks;2024-04-10

5. Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across Australia;Open Forum Infectious Diseases;2024-03-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3